Literature DB >> 2639304

The distribution of trypsin-like enzyme activity in cultures of a virulent and an avirulent strain of Bacteroides gingivalis W50.

J W Smalley, A J Birss, H M Kay, A S McKee, P D Marsh.   

Abstract

The distribution of trypsin-like enzyme activity was studied in 48- and 72-h batch cultures of Bacteroides gingivalis W50 and an avirulent variant (W50/BE1) of the parent strain. Activity was measured at pH 7.4 in cells, the extracellular vesicle (ECV) and soluble extracellular protein (EP) fractions recovered by ammonium sulphate precipitation from spent growth medium. Both organisms produced cell surface and extracellular vesicles, but whilst strain W50 produced more ECV, W50/BE1 yielded more of the EP fraction by weight. Whole cultures of W50 displayed a three-fold greater trypsin activity than those of W50/BE1. However, 90% of the total enzyme activity of W50 cultures was associated with the particulate fraction (cells and ECV totalled), whereas this fraction accounted for only 10-30% of the total for W50/BE1. Unlike W50/BE1, the specific activities of W50 cells and ECV rose in 72-h cultures. Conversely, cultures of W50/BE1 displayed an increase in the yield and specific activity of the EP fraction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2639304     DOI: 10.1111/j.1399-302x.1989.tb00249.x

Source DB:  PubMed          Journal:  Oral Microbiol Immunol        ISSN: 0902-0055


  15 in total

1.  Activation of blood coagulation factor IX by gingipains R, arginine-specific cysteine proteinases from Porphyromonas gingivalis.

Authors:  T Imamura; S Tanase; T Hamamoto; J Potempa; J Travis
Journal:  Biochem J       Date:  2001-01-15       Impact factor: 3.857

2.  Role of Porphyromonas gingivalis protease activity in colonization of oral surfaces.

Authors:  M Tokuda; M Duncan; M I Cho; H K Kuramitsu
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

3.  Crystallization and preliminary X-ray diffraction analysis of gingipain R2 from Porphyromonas gingivalis in complex with H-D-Phe-Phe-Arg-chloromethylketone.

Authors:  A Banbula; J Potempa; J Travis; W Bode; F J Medrano
Journal:  Protein Sci       Date:  1998-05       Impact factor: 6.725

4.  RgpA-Kgp peptide-based immunogens provide protection against Porphyromonas gingivalis challenge in a murine lesion model.

Authors:  N M O'Brien-Simpson; R A Paolini; E C Reynolds
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

5.  Inhibition of trypsin-like cysteine proteinases (gingipains) from Porphyromonas gingivalis by tetracycline and its analogues.

Authors:  T Imamura; K Matsushita; J Travis; J Potempa
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

6.  A novel mouse model to study the virulence of and host response to Porphyromonas (Bacteroides) gingivalis.

Authors:  C A Genco; C W Cutler; D Kapczynski; K Maloney; R R Arnold
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

7.  Effect of free and vesicle-bound cysteine proteinases of Porphyromonas gingivalis on plasma clot formation: implications for bleeding tendency at periodontitis sites.

Authors:  T Imamura; J Potempa; R N Pike; J N Moore; M H Barton; J Travis
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

8.  The multiple forms of trypsin-like activity present in various strains of Porphyromonas gingivalis are due to the presence of either Arg-gingipain or Lys-gingipain.

Authors:  J Potempa; R Pike; J Travis
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

9.  Pathogenesis of periodontitis: a major arginine-specific cysteine proteinase from Porphyromonas gingivalis induces vascular permeability enhancement through activation of the kallikrein/kinin pathway.

Authors:  T Imamura; R N Pike; J Potempa; J Travis
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

10.  Dependence of vascular permeability enhancement on cysteine proteinases in vesicles of Porphyromonas gingivalis.

Authors:  T Imamura; J Potempa; R N Pike; J Travis
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.